Literature DB >> 6404549

Protective activity of thymosin against opportunistic infections in animal models.

H Ishitsuka, Y Umeda, J Nakamura, Y Yagi.   

Abstract

Animal models for opportunistic infections were developed by using mice immunosuppressed by 5-FU. These mice were susceptible to various microorganisms, while normal mice had greater tolerance to such microbial infections. In these models, thymosin alpha 1 was found to protect mice against lethal infections with Candida albicans, Listeria monocytogenes, Pseudomonas aeruginosa, and Serratia marcescens when it was administered during 5-FU treatment prior to the infections. Thymosin alpha 1 was effective in some infections at 0.4-400 micrograms/kg/day IP, about 1/100 of the dose required for thymosin fraction 5. Activity was also demonstrated against L-monocytogenes and Ps. aeruginosa by counting the viable bacteria in the liver after infection. The protective activity against Candida, elimination of which macrophages were essential, was abrogated by anti-thymocyte serum and/or carrageenan, indicating that thymosin alpha 1 serves to maintain the functions of macrophages by reducing the damage to T cells by 5-FU. On the other hand, the activity against Pseudomonas infection was not affected by anti-thymocyte serum or carrageenan. It is probable that thymosin alpha 1 also exerts its effect on neutrophils without participation of T cells and macrophages.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404549     DOI: 10.1007/BF00205352

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

Review 1.  Infections in cancer patients.

Authors:  G P Bodey
Journal:  Cancer Treat Rev       Date:  1975-06       Impact factor: 12.111

Review 2.  SPECIFIC AND NONSPECIFIC IMMUNITY IN CANDIDA INFECTIONS. EXPERIMENTAL STUDIES OF THE ROLE OF CANDIDA CELL CONSTITUENTS AND REVIEW OF LITERATURE.

Authors:  B DOBIAS
Journal:  Acta Med Scand       Date:  1964

3.  Fluorinated pyrimidines. VI. Effects of 5-fluorouridine and 5-fluoro-2'-deoxyuridine on transplanted tumors.

Authors:  C HEIDELBERGER; L GRIESBACH; O CRUZ; R J SCHNITZER; E GRUNBERG
Journal:  Proc Soc Exp Biol Med       Date:  1958-02

4.  Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide.

Authors:  A L Goldstein; T L Low; M McAdoo; J McClure; G B Thurman; J Rossio; C Y Lai; D Chang; S S Wang; C Harvey; A H Ramel; J Meienhofer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

5.  Thymosin treatment modulates production of interferon.

Authors:  K Y Huang; P D Kind; E M Jagoda; A L Goldstein
Journal:  J Interferon Res       Date:  1981

6.  Differing contribution of polymorphonuclear cells and macrophages to protection of mice against Listeria monocytogenes and Pseudomonas aeruginosa.

Authors:  K Tatsukawa; M Mitsuyama; K Takeya; K Nomoto
Journal:  J Gen Microbiol       Date:  1979-11

7.  Induction of terminal deoxynucleotidyl transferase and Lyt antigens with thymosin: identification of multiple subsets of prothymocytes in mouse bone marrow and spleen.

Authors:  I Goldschneider; A Ahmed; F J Bollum; A L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

8.  Spectrum and possible mechanism of carrageenan cytotoxicity.

Authors:  P J Catanzaro; H J Schwartz; R C Graham
Journal:  Am J Pathol       Date:  1971-08       Impact factor: 4.307

9.  Thymosin activity in patients with cellular immunodeficiency.

Authors:  D W Wara; A L Goldstein; N E Doyle; A J Ammann
Journal:  N Engl J Med       Date:  1975-01-09       Impact factor: 91.245

10.  Induction in vivo and in vitro of terminal deoxynucleotidyl transferase by thymosin in bone marrow cells from athymic mice.

Authors:  N H Pazmiño; J N Ihle; A L Goldstein
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Thymic hormones--a clinical update.

Authors:  M B Sztein; A L Goldstein
Journal:  Springer Semin Immunopathol       Date:  1986

2.  Primary structure of rat thymus prothymosin alpha.

Authors:  A A Haritos; R Blacher; S Stein; J Caldarella; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

3.  Immunomodulating activity of thymosin fraction 5 and thymosin alpha 1 in immunosuppressed mice.

Authors:  Y Ohta; K Sueki; Y Yoneyama; E Tezuka; Y Yagi
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays.

Authors:  Y Umeda; A Sakamoto; J Nakamura; H Ishitsuka; Y Yagi
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

5.  Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus.

Authors:  A A Haritos; G J Goodall; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

6.  Thymosin alpha 11: a peptide related to thymosin alpha 1 isolated from calf thymosin fraction 5.

Authors:  J Caldarella; G J Goodall; A M Felix; E P Heimer; S B Salvin; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

7.  The human prothymosin alpha gene is polymorphic and induced upon growth stimulation: evidence using a cloned cDNA.

Authors:  W H Eschenfeldt; S L Berger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  The primary structure of rat parathymosin.

Authors:  T Komiyama; L X Pan; A A Haritos; J W Wideman; Y C Pan; M Chang; I Rogers; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.